Notice of results and investor briefing

RNS Number : 4892T

Creo Medical Group PLC

21 March 2019

 

                                                                                               Creo Medical Group plc

("Creo" or the "Company")

Notice of results and investor briefing

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, will announce its final results for the 18 month period to 31 December 2018 on Friday 5 April 2019.

Investor briefing

A briefing for investors will take place on Tuesday 9 April 2019 at the Brand Exchange, 3 Birchin Lane, EC3V 9BW at 5.15pm for a 5.30pm start and will be followed by refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email [e-mail]

- Ends -

For further information please contact:

Creo Medical Group plc
Richard Rees (CFO)	[phone]
Cenkos Securities	[phone]
Stephen Keys / Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Helen Cresswell	Mob: [phone]

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

 

END

 

 

NORZMGZFKGRGLZM